Chochua Sopio, Beall Bernard, Lin Wuling, Tran Theresa, Rivers Joy, Li Zhongya, Arvay Melissa L, Kobayashi Miwako, Houston Jessica, Arias Sabra, McGee Lesley
Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases.
Eagle Global Scientific, LLC, Contractor to Respiratory Diseases Branch.
J Infect Dis. 2025 Mar 17;231(3):746-750. doi: 10.1093/infdis/jiae393.
We report a single case of invasive pneumococcal disease (IPD) by serotype 4, multilocus sequence type 10172 (ST10172) isolate with vanG-type resistance genes and reduced vancomycin susceptibility. The isolate was recovered during 2022 from a 66-year-old resident with bacteremic pneumococcal pneumonia within a Centers for Disease Control and Prevention Active Bacterial Core surveillance (ABCs) site hospital. The patient had received 23-valent pneumococcal polysaccharide vaccine and there was no evidence of concurrent or prior receipt of vancomycin in the previous year. Serotype 4/ST10172 IPD has shown increases within western ABCs sites, and the recent acquisition of a vanG element warrants close monitoring of this lineage.
我们报告了一例由4型血清型、多位点序列类型10172（ST10172）分离株引起的侵袭性肺炎球菌病（IPD），该分离株带有vanG型耐药基因且对万古霉素敏感性降低。该分离株于2022年从疾病控制与预防中心主动细菌核心监测（ABCs）站点医院的一名患有菌血症性肺炎球菌肺炎的66岁住院患者中分离得到。该患者已接种23价肺炎球菌多糖疫苗，且没有证据表明其在前一年同时或之前接受过万古霉素治疗。4型血清型/ST10172 IPD在西部ABCs站点有所增加，最近获得的vanG元件值得对该谱系进行密切监测。
